Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 57.60M | 55.31M | 36.84M | 29.53M | 35.69M |
| Total Other Revenue | -- | -- | -- | -- | 100.00K |
| Total Revenue | 57.60M | 55.31M | 36.84M | 29.53M | 35.79M |
| Cost of Revenue | 11.42M | 14.21M | 8.35M | 8.05M | 6.98M |
| Gross Profit | 46.18M | 41.10M | 28.49M | 21.48M | 28.82M |
| SG&A Expenses | 29.52M | 27.04M | 28.05M | 28.45M | 26.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.94M | 41.25M | 36.39M | 36.50M | 33.83M |
| Operating Income | 16.66M | 14.06M | 447.00K | -6.97M | 1.97M |
| Income Before Tax | 15.22M | 12.42M | -1.03M | -8.25M | 737.00K |
| Income Tax Expenses | 881.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.34M | 12.42M | -1.03M | -8.25M | 737.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.34M | 12.42M | -1.03M | -8.25M | 737.00K |
| EBIT | 16.66M | 14.06M | 447.00K | -6.97M | 1.97M |
| EBITDA | 17.26M | 14.67M | 1.06M | -6.57M | 2.26M |
| EPS Basic | 0.81 | 0.71 | -0.06 | -0.47 | 0.04 |
| Normalized Basic EPS | 0.54 | 0.44 | -0.04 | -0.29 | 0.03 |
| EPS Diluted | 0.80 | 0.70 | -0.06 | -0.50 | 0.04 |
| Normalized Diluted EPS | 0.53 | 0.44 | -0.04 | -0.29 | 0.03 |
| Average Basic Shares Outstanding | 17.65M | 17.60M | 17.55M | 17.52M | 17.44M |
| Average Diluted Shares Outstanding | 17.99M | 17.65M | 17.55M | 17.52M | 17.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |